The Interleukin 3 Gene (IL3) Contributes to Human Brain Volume Variation by Regulating Proliferation and Survival of Neural Progenitors.

University of Rochester Flaum Eye Institute, University of Rochester, Rochester, New York, United States of America.
PLoS ONE (Impact Factor: 3.53). 11/2012; 7(11):e50375. DOI: 10.1371/journal.pone.0050375
Source: PubMed

ABSTRACT One of the most significant evolutionary changes underlying the highly developed cognitive abilities of humans is the greatly enlarged brain volume. In addition to being far greater than in most other species, the volume of the human brain exhibits extensive variation and distinct sexual dimorphism in the general population. However, little is known about the genetic mechanisms underlying normal variation as well as the observed sex difference in human brain volume. Here we show that interleukin-3 (IL3) is strongly associated with brain volume variation in four genetically divergent populations. We identified a sequence polymorphism (rs31480) in the IL3 promoter which alters the expression of IL3 by affecting the binding affinity of transcription factor SP1. Further analysis indicated that IL3 and its receptors are continuously expressed in the developing mouse brain, reaching highest levels at postnatal day 1-4. Furthermore, we found IL3 receptor alpha (IL3RA) was mainly expressed in neural progenitors and neurons, and IL3 could promote proliferation and survival of the neural progenitors. The expression level of IL3 thus played pivotal roles in the expansion and maintenance of the neural progenitor pool and the number of surviving neurons. Moreover, we found that IL3 activated both estrogen receptors, but estrogen didn't directly regulate the expression of IL3. Our results demonstrate that genetic variation in the IL3 promoter regulates human brain volume and reveals novel roles of IL3 in regulating brain development.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Genetics Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI), formally established in 2009, aims to provide resources and facilitate research related to genetic predictors of multidimensional Alzheimer's disease (AD)-related phenotypes. Here, we provide a systematic review of genetic studies published between 2009 and 2012 where either ADNI APOE genotype or genome-wide association study (GWAS) data were used. We review and synthesize ADNI genetic associations with disease status or quantitative disease endophenotypes including structural and functional neuroimaging, fluid biomarker assays, and cognitive performance. We also discuss the diverse analytical strategies used in these studies, including univariate and multivariate analysis, meta-analysis, pathway analysis, and interaction and network analysis. Finally, we perform pathway and network enrichment analyses of these ADNI genetic associations to highlight key mechanisms that may drive disease onset and trajectory. Major ADNI findings included all the top 10 AD genes and several of these (e.g., APOE, BIN1, CLU, CR1, and PICALM) were corroborated by ADNI imaging, fluid and cognitive phenotypes. ADNI imaging genetics studies discovered novel findings (e.g., FRMD6) that were later replicated on different data sets. Several other genes (e.g., APOC1, FTO, GRIN2B, MAGI2, and TOMM40) were associated with multiple ADNI phenotypes, warranting further investigation on other data sets. The broad availability and wide scope of ADNI genetic and phenotypic data has advanced our understanding of the genetic basis of AD and has nominated novel targets for future studies employing next-generation sequencing and convergent multi-omics approaches, and for clinical drug and biomarker development.
    Brain Imaging and Behavior 10/2013; DOI:10.1007/s11682-013-9262-z · 2.67 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Many aspects of autoimmune disease are not well understood, including the specificities of autoimmune targets, and patterns of co-morbidity and cross-heritability across diseases. Prior work has provided evidence that somatic mutation caused by gene conversion and deletion at segmentally duplicated loci is relevant to several diseases. Simple tandem repeat (STR) sequence is highly mutable, both somatically and in the germ-line, and somatic STR mutations are observed under inflammation.
    PLoS ONE 07/2014; 9(7):e101093. DOI:10.1371/journal.pone.0101093 · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The involvement of cytokines in schizophrenia (SZ) has been proposed in recent years and various studies have accumulated convergent lines of evidence. Among which, the role of interleukin-10 (IL-10) in SZ has been explored in a number of studies by investigating association of single nucleotide polymorphisms (SNPs) and susceptibility of SZ. However, the results are inconsistent since its power is limited by the individual sample size. To evaluate the overall effect between them, we conducted a meta-analysis by combining all available studies. Studies were searched from the database of PubMed, PsycINFO and ISI web of Knowledge up to Nov 2013. The meta-analysis was conducted based on statement of preferred reporting items for systematic reviews and meta-analyses (PRISMA). Eleven studies including 6399 subjects (3129 cases and 3270 controls) were available for the meta-analysis. Among three investigated SNPs, rs1800872 was observed to be significantly associated with risk of SZ (AA vs. AC+CC, Pooled OR = 1.351, P-value = 2.06E-04). Meanwhile, among six haplotypes of rs1800896 - rs1800871 - rs1800872, significant associations were observed in haplotype A-C-A (Pooled OR = 1.762, P-value = 2.00E-03) and G-C-C (Pooled OR = 0.649, P-value = 2.00E-03) for Asians. These results were still significant after adjusting for multiple comparisons. This meta-analysis demonstrated an SNP and two haplotypes of IL-10 significantly associated with SZ, suggesting that IL-10 might be a risk factor of SZ.
    PLoS ONE 03/2014; 9(3):e90407. DOI:10.1371/journal.pone.0090407 · 3.53 Impact Factor


Available from
May 31, 2014